Dexmedetomidine Versus Hyalase Treatment of Carpal Tunnel Syndrome

Dexmedetomidine Versus Hyalase Local Injection for Pain Alleviation in Patients With Carpal Tunnel Syndrome; A Randomized Clinical Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05280223

Enrollment

Registered

2022-03-15

Start date

2022-04-01

Completion date

2023-08-25

Last updated

2023-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carpal Tunnel Syndrome, Pain, Chronic

Brief summary

Carpal tunnel syndrome (CTS) is a common peripheral entrapment neuropathy, this study aims to investigate if, and to what extent hydro-dissection hyalase and saline versus dexmedetomidine upon the median nerve could offer symptoms and clinical improvement

Detailed description

Carpal tunnel syndrome (CTS) is the most common compression syndrome the upper extremities. Its problem has a high prevalence ranged estimated prevalence of 3.8% in the general population, 3 and 7.8% in the working population. It occurs at any age, especially in individuals in their 40s to 60s, and the male: female ratio is reported to be 3:7. A lot of treatment modalities have been tried to improve the condition, starting from local anesthetic injection, steroid, and up to surgical decompression of the nerves.

Interventions

DRUGDexmedetomidine

injection of 1 microgram/kg dexmeditomidine + 10 cc saline injection nearby median nerve as hydrodissection

DRUGHyalase

injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* adult patients * complaining of carpal tunnel syndrome of 3 month duration or more * diagnosed axonal neuropathy using electrodiagnosis , nerve conduction study

Exclusion criteria

* • patient refusal infection at the site of intervention * local anesthetic allergy

Design outcomes

Primary

Measure	Time frame	Description
Pain alleviation	6 months	pain alleviation improvement of pain measured by visual analog scale , no pain the scale equal zero , and worst pain the scale equal 10

Secondary

Measure	Time frame	Description
Median nerve cross sectional area	6 months	Changes in ultrasound imaging change of cross sectional area in cubic mellimeter

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026